Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments

Mehmood, Rao Khalid

doi:10.4081/oncol.2014.256

Cited by 67 publications

(64 citation statements)

References 88 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin is a commonly used chemotherapeutic drug[ 8 ], while pemetrexed is a recently developed compound that has been reported to have a favorable toxic effect against gastric cancer cell lines[ 12 ]. The combination of pemetrexed and cisplatin has been used to treat advanced lung adenocarcinoma and malignant mesothelioma [ 13 , 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin is a frequently used chemotherapeutic drug that plays an anti-cancer role by binding to genomic DNA, causing DNA damage and ultimately leading to cell death [ 8 – 10 ]. Previous studies have suggested that cisplatin induces cell death by down-regulating the telomerase activity of choroidal melanoma cells in a dose- and time-dependent manner [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…In many clinical cases, cisplatin is combined with other drugs to reduce adverse side effects and achieve better therapeutic activity [ 8 ]. Pemetrexed, a recently developed anti-folate compound with favorable toxic effects, is well tolerated by patients and has shown cytotoxicity against breast and lung cancer cell lines [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells

et al. 2017

View full text Add to dashboard Cite

Choroidal melanoma is the most common primary malignant intraocular tumor, and very few effective therapies are available to treat it. Our study aimed to understand whether pemetrexed plus cisplatin exerts a beneficial synergistic effect in human choroidal melanoma cells and to delineate the underlying molecular mechanism. To accomplish these aims, we treated choroidal melanoma cells with pemetrexed and cisplatin and assessed cell survival with SRB and MTT assays. Proteins were detected using western blotting analysis. NOXA and CHOP were knocked down with siRNA. We found that pemetrexed or cisplatin alone inhibited survival and induced apoptosis in human choroidal melanoma cells. Furthermore, the expression levels of c-FLIP, an anti-apoptotic protein in the extrinsic apoptosis pathway, and Mcl-1, an anti-apoptotic protein in the intrinsic apoptosis pathway, were decreased by pemetrexed or cisplatin respectively, while the expression of a pro-apoptotic protein in the intrinsic apoptosis pathway, NOXA, was up-regulated. Moreover, pemetrexed or cisplatin alone increased the protein expression of the endoplasmic reticulum stress markers IRE1α, Bip and CHOP. Silencing CHOP expression reduced NOXA expression. These findings suggest that the pemetrexed or cisplatin induced intrinsic apoptosis via activation of the ER stress response. Importantly, combining the two compounds more strongly induced apoptosis. Following the cotreatment, CHOP and NOXA expression increased, while c-FLIP and Mcl-1 expression decreased, and these effects were more pronounced than when using either compound alone. This result suggests that pemetrexed and cisplatin synergistically activate ER stress response-induced apoptosis in choroidal melanoma cells. To summarize, the c-FLIP and NOXA/Mcl-1 axis participated in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells. Intrinsic apoptosis was induced via activation of the ER stress response. Our study provides important mechanistic insights into potential cancer treatment with pemetrexed plus cisplatin and enriches our understanding of human choroidal melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…While the nonsynergistic drug combinations, highlighted in blue in the table, such as cisplatin + oxaliplatin and gemcitabine + 5‐FU may result from their similar mechanism of action. Both cisplatin and oxaliplatin are DNA alkylating agents forming platinated intra‐strand and inter‐strand cross‐link, interfering with DNA replication . While gemcitabine and 5‐FU are both belongs to nucleoside analog family of medication, which induces cell apoptosis by inhibiting the synthesis of new DNA .…”

Section: Introductionmentioning

confidence: 99%

Scalable Multiplexed Drug‐Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine

Zhang

Chen

Urs

et al. 2018

Small

View full text Add to dashboard Cite

Cancer heterogeneity is a notorious hallmark of this disease, and it is desirable to tailor effective treatments for each individual patient. Drug combinations have been widely accepted in cancer treatment for better therapeutic efficacy as compared to a single compound. However, experimental complexity and cost grow exponentially with more target compounds under investigation. The primary challenge remains to efficiently perform a large‐scale drug combination screening using a small number of patient primary samples for testing. Here, a scalable, easy‐to‐use, high‐throughput drug combination screening scheme is reported, which has the potential of screening all possible pairwise drug combinations for arbitrary number of drugs with multiple logarithmic mixing ratios. A “Christmas tree mixer” structure is introduced to generate a logarithmic concentration mixing ratio between drug pairs, providing a large drug concentration range for screening. A three‐layer structure design and special inlets arrangement facilitate simple drug loading process. As a proof of concept, an 8‐drug combination chip is implemented, which is capable of screening 172 different treatment conditions over 1032 3D cancer spheroids on a single chip. Using both cancer cell lines and patient‐derived cancer cells, effective drug combination screening is demonstrated for precision medicine.

show abstract

“…1 Chemotherapy for CRC mainly relies on fluoropyrimidine compounds combined with platinum drugs, mainly cisplatin and its analogues carboplatin and oxaliplatin, being this latter the leading Ptbased drug for the treatment of this pathology. 2 Oxaliplatin (Eloxatin™) is a third-generation platinum compound approved by United States Food and Drug Administration (FDA) on 2002 for the treatment of advanced CRC. To date thousands of patients worldwide have been treated with oxaliplatin, especially in combination with other drugs.…”

Section: Introductionmentioning

confidence: 99%

Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation

Marzo

Pratesi

Cirri

et al. 2018

Inorganica Chimica Acta

View full text Add to dashboard Cite

Despite the widespread use of platinum drugs in the treatment of colorectal cancer (CRC), due to the heavy side effects and to intrinsic or acquired Pt resistance, new and more efficient drugs are urgently needed. Starting from the encouraging results obtained for the complex PtI2(DACH), we summarise here our recent advances, reporting data on the synthesis, on the chemical and biological features of two oxaliplatin analogues i.e. PtBr2(DACH) and PtCl2(DACH). The comparative approach of these studies reveals how these analogues possess interesting and differential pharmacological properties as well as some peculiar features that may be conveniently exploited to shed light in the mechanistic aspects involved in the pharmacological action of the parent drug. Furthermore, these findings are suitable for the design of more effective Pt-based anticancer drugs to be used in CRC treatment.

show abstract

Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments

Cited by 67 publications

References 88 publications

c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells

c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells

Scalable Multiplexed Drug‐Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine

Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation

Contact Info

Product

Resources

About